Why Multifamily Properties Are a Smart Play for Real Estate Investors in 2026

Picture this: a bustling apartment complex filled with tenants who reliably pay rent every month. The building stands strong through economic ups and downs, offering steady cash flow and long-term appreciation. This isn’t just a dream scenario-it’s the reality many real estate investors are chasing in 2026 by focusing on multifamily properties.

With shifting demographics, evolving market dynamics, and changing tenant preferences, multifamily real estate is carving out a unique niche as a resilient and lucrative investment. Here’s why this multifamily property real estate investing deserves serious attention this year.

Rising Demand for Rental Housing

One of the biggest drivers behind the multifamily boom is the surging demand for rental units. Homeownership rates have dipped slightly in recent years, partly due to affordability challenges and lifestyle preferences. Younger generations, especially Millennials and Gen Z, are renting longer and prioritizing flexibility over owning a home.

According to recent data from the U.S. Census Bureau, the national homeownership rate hovered around 65% in early 2026, down from a peak near 69% a decade ago. Meanwhile, rental vacancy rates remain low, often below 5% in many urban and suburban markets. This tight supply-demand balance pushes rents upward, benefiting multifamily landlords.

Additionally, the rise of remote work has expanded the geographic appeal of rental properties. People are no longer tethered to city centers and are seeking multifamily communities in suburban and secondary markets. This trend widens the pool of potential tenants and creates new opportunities for investors willing to look beyond traditional hotspots.

Demographic Shifts Fueling Growth

Baby Boomers downsizing, young professionals delaying home purchases, and immigrants settling in urban areas all contribute to the growing renter population. The U.S. Census projects that by 2030, over 60% of households will rent at least once in their lifetime, underscoring the long-term nature of this trend.

Multifamily properties cater well to these groups by offering amenities, convenience, and community. Investors who understand these demographic nuances can better position their portfolios for sustained demand.

Furthermore, the increasing popularity of urban living among younger generations has led to a surge in demand for rental units that provide not just a place to live, but a lifestyle. Many multifamily developments now feature co-working spaces, fitness centers, and social lounges, creating environments that foster community interaction and cater to the needs of a diverse tenant base. This shift towards lifestyle-oriented living is particularly appealing to Millennials and Gen Z, who often prioritize experiences and social connectivity over traditional markers of success like homeownership.

Moreover, the influx of technology and innovation into the rental market has transformed how properties are managed and marketed. Smart home features, eco-friendly building practices, and enhanced digital communication channels are becoming standard expectations for renters. As these technological advancements continue to evolve, they not only improve the living experience but also increase operational efficiencies for property managers, making multifamily investments even more attractive in a competitive landscape.

Economies of Scale and Operational Efficiency

Managing a single-family rental is one thing; handling dozens or hundreds of units under one roof is another. Multifamily properties offer significant economies of scale that can improve profitability and reduce headaches.

For starters, maintenance and management costs per unit tend to be lower in multifamily buildings. Instead of dispatching a contractor to multiple scattered houses, repairs can be centralized. Property management teams can operate more efficiently, and bulk purchasing of supplies reduces expenses. This centralized approach not only streamlines operations but also fosters stronger relationships with service providers, who may offer better rates or priority service due to the volume of business.

This efficiency translates into higher net operating income (NOI) and better margins. It also makes it easier to implement upgrades or retrofit buildings with energy-saving technologies, which tenants increasingly value. Additionally, the ability to implement uniform policies and procedures across all units can enhance tenant satisfaction, as residents enjoy consistent service and amenities, contributing to higher retention rates.

Mitigating Vacancy Risks

Vacancy risk is a major concern for any landlord. With single-family homes, a vacant property means zero income until a new tenant moves in. Multifamily properties spread that risk across multiple units. If one apartment sits empty, the rest still generate cash flow, cushioning the impact.

This diversification within a single asset makes multifamily investments more resilient during economic downturns or local market fluctuations. Investors can weather short-term vacancies without jeopardizing their overall financial health. Moreover, multifamily properties often attract a diverse tenant base, from young professionals to families, which can further stabilize occupancy rates. The ability to adapt marketing strategies to target various demographics allows property managers to fill vacancies more quickly, ensuring a steady stream of income even in challenging market conditions.

Attractive Financing and Investment Structures

Financing multifamily properties has become more accessible and favorable in 2026. Lenders recognize the stability of this asset class and often offer competitive interest rates and longer amortization periods compared to other commercial real estate sectors.

Government-backed programs, like those from Fannie Mae and Freddie Mac, provide attractive loan options for multifamily investors, especially for properties with five or more units. These programs often feature lower down payments and flexible underwriting standards.

Moreover, multifamily assets fit well into various investment structures-from individual ownership to syndications and real estate investment trusts (REITs). This flexibility allows investors with different risk tolerances and capital levels to participate.

Leveraging Technology and Data Analytics

Technology is transforming how multifamily properties are bought, managed, and optimized. Advanced data analytics help investors identify emerging markets, forecast rent growth, and assess property performance with greater precision.

Property management software streamlines tenant communications, rent collection, and maintenance requests, improving tenant satisfaction and retention. Smart home devices and energy management systems reduce operating costs and appeal to tech-savvy renters.

Investors who embrace these tools gain a competitive edge by maximizing operational efficiency and enhancing the tenant experience.

Resilience in Uncertain Economic Times

Economic uncertainty often shakes investor confidence, but multifamily properties have historically proven to be a safe harbor. During recessions, rental demand tends to rise as fewer people can afford to buy homes. This counter-cyclical nature makes multifamily real estate investing a valuable portfolio diversifier.

The 2020 pandemic underscored this resilience. While many commercial real estate sectors struggled, multifamily housing remained relatively stable. Rent collections dipped briefly but rebounded quickly, supported by government stimulus and tenant demand.

Looking ahead, inflation concerns and rising interest rates make fixed-income investments less attractive. Multifamily properties, with their potential for rent increases tied to inflation, offer a hedge against eroding purchasing power.

Long-Term Appreciation Potential

Beyond cash flow, multifamily properties can appreciate significantly over time. Urbanization trends, infrastructure investments, and demographic shifts support steady property value growth in many markets.

Investors who acquire well-located properties and maintain them effectively can benefit from capital appreciation alongside rental income. Strategic renovations and repositioning can unlock additional value, turning older buildings into highly sought-after communities.

Challenges to Consider

No investment is without risks. Multifamily properties require active management and can involve complex regulatory environments, especially in rent-controlled cities. Property taxes, insurance, and maintenance costs can fluctuate, impacting profitability.

Competition for quality assets is intense, driving prices up in some markets. Investors must conduct thorough due diligence, including market analysis, financial modeling, and property inspections, to avoid overpaying or underestimating expenses.

Tenant turnover and compliance with fair housing laws also demand attention. Building strong relationships with tenants and maintaining transparent communication helps reduce vacancies and legal issues.

Final Thoughts

Multifamily real estate stands out in 2026 as a compelling investment choice. The combination of strong rental demand, operational efficiencies, favorable financing, and economic resilience creates a powerful value proposition.

Investors who approach this sector with careful research, strategic planning, and a willingness to leverage technology are well-positioned to capitalize on its advantages. Whether seeking steady income, portfolio diversification, or long-term growth, multifamily properties offer a smart path forward in today’s complex real estate landscape.

Metformin for Longevity: Understanding Its Anti-Aging Potential

Metformin has been used for decades. Not as a wellness trend. Not as a supplement experiment. As a prescription drug with a long safety record in metabolic disease. What has changed is how researchers now view the drug. Instead of asking only how Metformin lowers blood glucose, the question has widened. Can Metformin support longevity? And if so, how?

This article focuses on Metformin and healthy aging. Not hype. Not promises. Just what the evidence shows so far, why researchers keep paying attention, and where people often misunderstand what Metformin can and cannot do when used for long-term health goals.

Why Metformin Entered the Longevity Conversation

Longevity research often starts in unexpected places. In this case, it started with population data. Large observational studies noticed something unusual. People with type 2 diabetes taking Metformin often lived as long as, or longer than, people without diabetes. That outcome runs against expectations. Diabetes typically shortens lifespan. Yet in multiple datasets, Metformin users showed lower all-cause mortality than comparable groups using other metabolic therapies.

That observation didn’t prove causation. But it was strong enough to raise questions.

From there, researchers began studying Metformin beyond glucose control. Vascular health     . Inflammation markers. Cellular senescence     . Mitochondrial stress responses. These pathways matter not just for diabetes, but for aging itself.

Metformin for longevity entered serious scientific discussion because it touched many of the same biological processes that accelerate aging.

How Metformin Interacts with Aging Pathways

Aging is not one process. It is a collection of slow, cumulative changes that affect cells, tissues, and systems. Metformin appears to influence several of those areas at once.

One major mechanism involves insulin sensitivity. Chronically high insulin levels are linked to metabolic dysfunction, cardiovascular disease, and faster biological aging. Metformin improves insulin sensitivity, which lowers circulating insulin demand over time. That matters for long-term metabolic stability.

Another area involves cellular stress response systems. Metformin activates AMPK, an enzyme that helps cells respond to low-energy states, like fasting. AMPK activation is associated with improved cellular repair processes and enhanced mitochondrial function     . That balance becomes more important with age.

Inflammation also plays a role. Low-grade chronic inflammation increases as people age. This process, sometimes called inflammaging, contributes to cardiovascular disease, neurodegeneration, and metabolic decline. Metformin has been shown to reduce inflammatory signaling in multiple studies.

None of this means Metformin stops aging. But it may slow specific processes that drive age-related disease.

Metformin Anti-Aging Research: What the Evidence Actually Shows

Much of the strongest evidence comes from observational studies and animal models. In rodents, Metformin has extended lifespan under certain conditions. In humans, large population studies show reduced risk of cardiovascular events, lower cancer incidence     , and reduced mortality      compared to other glucose-lowering drugs.

The most discussed human study in this space is the proposed TAME trial, short for Targeting Aging with Metformin. The goal is not to prove immortality. The goal is to test whether Metformin can delay the onset of multiple age-related diseases at once. That includes heart disease, cancer, cognitive decline, and mortality.

This approach matters. Aging research has shifted away from treating one disease at a time. Instead, researchers are testing whether slowing underlying aging biology reduces multiple conditions together. Metformin fits that framework better than many newer drugs because of its long clinical history.

Metformin anti-aging research continues to grow because it is testable, measurable, and grounded in known biology.

Metformin and Cardiovascular Aging

Cardiovascular disease remains the leading cause of death worldwide. Aging increases arterial stiffness, endothelial dysfunction, and plaque formation. Metformin has shown benefits in several of these areas.

Studies have linked Metformin use to reduced risk of heart attack      and stroke in people with metabolic disease. Some data suggests benefits extend beyond glucose control alone. Improved lipid profiles. Reduced oxidative stress. Better endothelial function.

These effects matter for longevity because cardiovascular health sets the ceiling for lifespan in many individuals. Even modest reductions in cardiovascular risk compound over decades.

Metabolic Health as a Longevity Foundation

Longevity discussions often drift into abstract territory. But metabolic health remains central. Blood sugar regulation, insulin sensitivity, and cellular energy balance shape how the body ages.

Metformin improves metabolic efficiency. It reduces hepatic glucose production. It improves peripheral glucose uptake. It lowers insulin demand. Over time, those changes reduce metabolic strain.

For individuals focused on healthy aging, metabolic stability is not optional. It is foundational. Metformin for longevity is not about chasing youth. It is about reducing long-term metabolic damage that accelerates aging.

Common Misunderstandings About Metformin for Longevity

One mistake is thinking Metformin works the same way for everyone. Dose matters. Timing matters. Baseline metabolic health matters. Using too much or using it without medical guidance increases risk without added benefit.

Another mistake is assuming Metformin replaces lifestyle choices. Nutrition, physical activity, sleep, and stress management still dominate outcomes. Metformin works alongside those factors, not instead of them.

Some people also assume any Metformin source is equivalent. That assumption can cause real problems, especially when quality control and dosing oversight are missing.

The Longevity Conversation

As interest in Metformin for longevity grows, sourcing becomes critical. Prescription medications require precision. Not just in formulation, but in dosing, monitoring, and ongoing evaluation.

AgelessRx operates at that intersection. The platform focuses on longevity therapies while maintaining medical oversight. For Metformin, that means prescriptions are based on real clinical evaluation. Dosages are selected intentionally and tailored towards an individual’s goals. Patients are monitored by medical staff over time.

That structure matters. Longevity-focused use is different from short-term treatment. Long-term outcomes depend on consistency, authenticity of the medication, and appropriate dosing adjustments as needed over time. AgelessRx provides assurance that the product is real, regulated, and supported by clinicians who understand how Metformin fits into a broader healthy aging strategy.

Metformin is emerging as a potential anti-aging therapy partly because platforms like AgelessRx allow it to be used responsibly, with oversight, rather than as an unregulated experiment.

Where the Research Is Headed

Metformin remains one of the most studied drugs in aging research because it is affordable, widely available, safe and broadly effective     . Future studies will likely refine who benefits most, what dosing strategies work best, and how Metformin interacts with other longevity-focused therapies.

The question is no longer whether Metformin influences longevity     . The question is how to apply it with precision for maximum benefit     .

Can Metformin Support Longevity?

The evidence suggests Metformin supports healthier aging in specific ways. Improved metabolic control. Reduced inflammation. Better cardiovascular outcomes. Possible protection against a cluster of age-related diseases.      

Metformin for longevity is not a shortcut. It is a tool. One backed by decades of clinical use and a growing body of aging research. When used appropriately, with medical oversight, it fits into a realistic, evidence-based approach to extending healthspan.

Healthy aging does not come from one intervention. But Metformin continues to earn attention because it addresses core drivers of aging rather than surface symptoms.

That is why researchers keep studying it. And why interest continues to grow.

Ashton Kutcher returns to appearing in The Magnificence

Ashton Kutcher does not bother anyone with this beauty treatment.

At least the company doesn’t. After all, it is That 70s show Alum returned to acting after a three-year hiatus and starred in Ryan Murphyis the upcoming series The beauty, transforming ordinary people into works of art.

“I’m the world’s biggest damn advertisement for the hottest new super drug that will make you effortlessly beautiful,” Ashton’s character, simply called “The Corporation,” announced in the Jan. 5 trailer. “A simple injection to become a beauty.”

The intended effects can also be relayed in unconventional ways in the FX show, premiering Jan. 21 on Hulu. As the tech billionaire revealed, “It’s a sexually transmitted disease that people actually want.”

Unfortunately the injection appears have some unforeseen consequences and turn into a virus that leads to gruesome side effects and the gruesome death of supermodels. In fact, Bella Hadid‘s Ruby seems unable to contain her anger in a restaurant kitchen as she attacks chefs her Face Is burnt and blistered.

First GLP-1 anti-obesity capsule from Novo Nordisk launches within the US

The logo of pharmaceutical company Novo Nordisk is seen outside its offices in Bagsvaerd on the outskirts of Copenhagen on November 24, 2025.

Tom Little | Reuters

Novo Nordisk will begin rolling out the first-ever GLP-1 weight loss pill in the United States on Monday, the company announced, marking a new chapter in obesity treatment in the United States

The drug’s cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. That raises hopes that pills could help overcome the long-standing affordability hurdles associated with the weekly injections that dominate the weight-loss drug market.

The official launch of the oral drug, the Wegovy pill, comes just two weeks after US regulators approved the treatment.

The starting dose of 1.5 milligrams is available at more than 70,000 U.S. pharmacies, such as: CVS And Costcoas well as select telemedicine providers including Ro, LifeMD, Weight WatchersGoodRx and Novo Nordisk’s NovoCare Pharmacy. The higher, remaining doses of the pill will be available to patients by the end of the week, Novo Nordisk said.

Cash-paying patients can pay $149 per month for the initial dose. The 4-milligram dose of the pill will also be available for $149 per month until April 15, and $199 per month thereafter.

The highest doses of the Wegovy pill – 9 milligrams and 25 milligrams – will be available for $299 per month. Patients with insurance coverage for the drug can pay as little as $25 per month for treatment.

Patients who pay cash can also access initial doses of the pill for $149 a month on President Donald Trump’s direct-to-consumer website, TrumpRx, under an agreement Novo Nordisk struck with its government in November. The website will also launch in January, although it is unclear when.

Novo Nordisk said Monday that the availability of the pill “opens up new possibilities” for the more than 100 million Americans living with obesity.

Injections from Novo Nordisk and its main competitor Eli Lillyhave a list price of about $1,000 per month. However, both companies are offering lower cash prices for their vaccinations, ranging from $299 to $499 per month depending on the dose.

Pills are the next battleground for the two companies that founded the booming GLP-1 sector, which some analysts believe could be worth about $100 billion by the 2030s. Analysts at Goldman Sachs said in August that oral drugs could capture a 24% share – or about $22 billion – of the global weight-loss drug market in 2030.

Novo Nordisk’s daily oral drug launch on Monday gives the company a clear lead. The Food and Drug Administration approved the treatment on Dec. 22 and will decide later this year whether to withdraw a rival pill from Eli Lilly.

More CNBC Health coverage

The FDA also approved Novo Nordisk’s pill to reduce the risk of serious cardiovascular events, such as death, heart attack or stroke, in adults with obesity and existing cardiovascular disease.

This is in line with the approval of the company’s blockbuster weight loss drug Wegovy, which contains the same active ingredient semaglutide. Both work by mimicking the gut hormone GLP-1 to suppress appetite.

“This moment is about transforming the possibilities of weight management, and to make this possible we have worked to ensure this.” [the Wegovy pill] is affordable and accessible to those who need it, regardless of how they choose to receive care,” said Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk, in a press release.

People taking the Novo Nordisk pill must wait 30 minutes each day before eating or drinking.

In a Phase III trial that followed more than 300 adults with obesity rather than diabetes, Novo Nordisk’s highest dose of oral semaglutide helped patients lose an average of up to 16.6% of their weight after 64 weeks. That weight loss was 13.6% when the company analyzed all patients, regardless of whether they stopped taking the drug.

The pill appears to be slightly more effective than Eli Lilly’s experimental oral drug, which has no dietary restrictions.

The petty and infantile purpose Trump will not permit Machado to steer Venezuela

Donald Trump is by far the pettiest president in US history. He never forgets an insult, even if most of them are imagined, and he seeks revenge against people he sees as political enemies.

We have often seen this behavior in action in the United States, as even after their deaths Trump will continue to mock and criticize people like John McCain, whose unforgivable sin in Trump’s eyes was voting against repeal of the Affordable Care Act.

PoliticusUSA is not beholden to any particular interest or political party. We are 100% independent. Support us by becoming a subscriber.

Trump sought to launch revenge cases against those who had the courage to either speak out about potential wrongdoing in his first administration, like James Comey, or to successfully prosecute him, like New York State Attorney General Letitia James.

The courts have ensured that much of Trump’s agenda hits a wall, or at least faces obstacles, in the United States He has moved his pursuit of unlimited power and control overseas.

Venezuelan opposition leader María Corina Machado was widely expected to be the next president if Maduro was ever toppled from power. She was seen as the person who could usher in a new era of democracy in her home country.

Machado won’t get that chance because, according to new reports, she made the mistake of incurring Trump’s wrath He accepts the Nobel Peace Prize, which he covets.

Read more below.

Protection Shares Rise; The US assault on Venezuela heralds the period of “laborious energy”.

Defense stocks in Europe and Asia rose sharply on Monday as investors gauged that the dramatic ouster of Venezuelan leader Nicolas Maduro could herald a major geopolitical shift that will boost arms trade in the long run.

RheinmetallGermany’s largest arms maker, rose over 8%, while military technology and surveillance specialist Hensoldt rose more than 7%. of Italy Leonardo rose by more than 5%, while its German colleague Renk added around 8%.

Swedish manufacturer of fighter aircraft Saab added more than 6%.

Previously, Japan’s IHI Corp led the Asian defense stocks, up about 9%, followed closely by Mitsubishi Heavy Industrieswhich rose by more than 8%. Kawasaki Heavy Industriesmeanwhile, rose nearly 8%. In South Korea, Hanwa Aerospace closed 7% higher, while shares of Poongsan gained more than 2%.

There are now fighter jet giants in the USA Lockheed Martin and military aircraft manufacturer Northrop Grumman both rose more than 1%. The iShares US Aerospace & Defense ETF (ITA) rose more than 1% to hit a new all-time intraday record.

Fawaz Chaudhry, chief investment officer at Fulcrum Asset Management, said Maduro’s ouster was a “signaling exercise” that would change geopolitics.

“When President Trump invoked the Monroe Doctrine, he was talking about the near sphere in America taking control through hard power, through hard power resources,” Chaudhry said on CNBC’s “Europe Early Edition” on Monday.

“We’re talking about a world that’s trying to transition into a new era where we’re basically going to do it [have] “To give military installations hard power and take control, which is essentially a different policy than before.”

Chaudhry expects this more forceful US foreign policy approach will mean “more armament in Europe and Asia” in the longer term, adding that defense stockpiles and military spending will continue to rise.

“What President Trump and what America has just done in Venezuela will increase that. More military spending, more armament in Europe and Asia, so that trend will continue,” he explained.

New year, new world order

The gains by European defense contractors mark a significant turnaround for the sector, which has struggled in recent weeks amid the prospect of a possible peace deal between Ukraine and Russia.

Aoifinn Devitt, senior investment advisor at Moneta, expects defense spending to rise due to US exceptionalism and the “gunboat diplomacy” theme on display in recent days.

“We know that defense stocks actually fluctuated when it looked like there was peace in Ukraine. But ironically, if anything, this issue is particularly highlighted.” [by] “This rhetoric is spreading to neighboring countries,” Devitt told CNBC’s “Squawk Box Europe” on Monday.

More broadly, defense has several important structural tailwinds, Devitt said, pointing to an increase in German military spending that has been “fully supported” by the current German government.

“New year, new world order – I think we all have to accept that. This will drive precautionary defense spending,” Devitt noted. “Do we think this is a productive use of resources where we’re actually creating jobs and generating long-term economic growth? Probably not. But that’s where we need to go.”

Moneta's Aoifinn Devitt expects defense spending to rise amid 'gunboat diplomacy'

Stephen Dover, chief market strategist and head of the Franklin Templeton Institute, said other countries with territorial interests elsewhere could be emboldened by the Trump administration’s unilateral use of force.

The move is also likely to increase uncertainty about the dollar’s safe-haven role, Dover said in a note, “while raising further questions about the deterioration of international institutional pillars.”

“The latest action by the US military is therefore likely to reinforce the already begun trend of various countries around the world to invest more in their national security. This has been one of our most important investment themes since the Russian invasion of Ukraine.”

Comcast spinoff Versant (VSNT) begins buying and selling on Nasdaq

Versant Media Group, the spun-off portfolio of cable television networks and digital assets Comcastjoined the small cohort of public media companies on Monday as the industry expects continued disruption.

Versant began trading on the Nasdaq under the ticker symbol “VSNT,” opening at $45.17 per share.

The company’s so-called “when-issued” shares – a security that is expected to be issued and has been conditionally admitted to trading to give investors an early chance to buy shares – initially traded at $55 per share on Dec. 15 and ended at $46.65 per share on Friday. Early trading on Monday marked a decline of about 10%.

The company’s market cap is approximately $6.5 billion, with 145.76 million shares outstanding based on the spinoff ratio. As part of the spinoff, Comcast shareholders received one share of Versant for every 25 Comcast shares they owned.

“It took a year,” Versant CEO Mark Lazarus said on CNBC’s “Squawk Box” on Monday.

In November 2024, Comcast announced its intention to spin off the majority of NBCUniversal’s cable television networks, including MS Now (formerly MSNBC), CNBC, Golf Channel, USA, E!, Syfy and Oxygen, as well as digital properties Fandango, Rotten Tomatoes, GolfNow and Sports Engine.

“As part of Comcast and NBCU, we had different priorities as a company,” Lazarus said. “We made different decisions because we had a different company and a different strategy. Now we’re bringing that with us.” [assets] invest in their own company, we will be able to invest in them. We will invest organically… and hopefully the market will listen to what we say.”

Lazarus said “vertical scaling” was necessary to diversify the business and move away from reliance on pay-TV.

“While this is still a big, profitable piece for us, it won’t be the end game,” he said.

There are only a few traditional media companies that have gone public in recent years – largely because of the major challenges facing the industry as a result of the shift away from TV bundles and towards streaming.

In 2025 Newsmaxthe conservative cable news network, went public on the New York Stock Exchange and saw its shares soar quickly from their opening price of $14 per share. It has fallen sharply since its debut.

Instead, the media sector was characterized by a rush for consolidation and new M&A deals. Paramount Skydance completed its merger last year and CEO David Ellison has been active in acquisitions ever since. Warner Bros. Discoveryitself founded after a merger in 2022, started a sales process last year that led to a planned deal with Netflix. Paramount has now made a hostile offer to WBD shareholders to reverse the planned transaction with Netflix.

Versant CEO Mark Lazarus visits the floor of the New York Stock Exchange (NYSE) on July 21, 2025 in New York City, USA.

Brendan Mcdermid | Reuters

The spin-off from Versant was also a consequence of the disruptive media landscape. Its executives, led by CEO Lazarus, the former chairman of NBCUniversal’s media group, spent the final months of 2025 convincing Wall Street investors that the company’s future would focus on expanding the digital presence of its portfolio.

The company has also highlighted its strength in news and sports, the two programming categories that still reach the majority of television viewers. Although networks like those in the Versant portfolio are seeing financial declines, they are still profitable and attracting advertising dollars.

On Monday, Lazarus again pointed to Versant’s weight in sports and news, saying that 62% of the portfolio is in those two content areas.

“We have a really strong position,” Lazarus said.

In September, Versant reported declining revenue in recent years as consumers opted out of cable TV packages.

According to a filing with the Securities and Exchange Commission prior to the IPO, Versant’s assets generated revenue of $7.1 billion in 2024, down from $7.4 billion in 2023 and $7.8 billion in 2022. The company said its net income attributable to Versant was $1.4 billion in 2024, compared to $1.5 billion in 2024 year 2023 and $1.8 billion in 2022.

Shortly thereafter, rating agencies S&P Global and Fitch Ratings each issued BB ratings on the company’s debt and indicated a stable outlook, placing the company’s rating in junk territory. This was based on Versant’s plans to issue $2.75 billion of new senior secured debt to fund a one-time $2.25 billion cash distribution to Comcast and increase its balance sheet by $500 million, S&P said.

Versant’s low debt was a good sign for the company with both rating agencies and was a highlight of its presentation to Wall Street investors. Media companies like Warner Bros. Discovery are struggling with heavy debt loads while also struggling with declining cable TV subscribers and lower advertising revenue.

Both ratings agencies noted that the traditional TV landscape faces headwinds that S&P said are “offsetting the strength of the TV industry.” [Versant’s] Portfolio,” noting that linear distribution and advertising revenue from its networks accounted for more than 80% of total revenue.

Fitch said “viewers’ strong loyalty and engagement” with Versant’s television networks, as well as its conservative debt structure, are a positive sign for the company.

Versant executives said at a recent investor day presentation that the company plans to grow its digital business through acquisitions and investments.

—CNBC’s Gina Francolla contributed to this article.

Disclosure: Versant is the parent company of CNBC.

Kardashian-Jenner Halloween costumes over time

Speaking of Kourtney, she won’t hide her love for the holidays either. The Poosh creator recently shared a post that included photos of her spooky clown decorations and throwbacks of her and her husband Travis Barker Trick-or-treat in their Frankenstein costumes and the adorable Halloween books they have for their own little pumpkin: 23-month-old son Rocky Thirteen Barker.

And on October 23, Kourtney enjoyed a celebratory dinner with her family — which included children Mason Disick15; Penelope Disick13; And Reign Disick10 with ex Scott Disick as well as stepchildren Landon Barker22; Alabama Barker19; And Atiana De La Hoya26, from Travis’ previous marriage to Moaker– This included a tablescape decorated with skulls, crows and candles.

Still, fans will have to wait to find out what Khloe, Kim, Kourtney and the rest of the Kardashian-Jenner crew chose for their costumes this year. However, if holding out until October 31 scares you, read on to check out the looks from past Halloween events.

Promote ​​enterprise? The Trump tax legislation provides homeowners higher choices for cashing out

An exit sign is seen above US President Donald Trump as he speaks to reporters aboard Air Force One.

Saul Loeb | Afp | Getty Images

Are you thinking about selling your small business in a few years? The One Big Beautiful Bill Act could give you millions more.

President Donald Trump’s signature law, which went into effect in July, significantly expanded the benefits of qualified small business shares, meaning Now more companies have the option to convert to a C corporation to receive more favorable tax treatment. While this is likely a boon for recently launched AI startups that see their own exit strategies as a path to great riches, owners in many sectors of the economy can reap significant tax savings by considering a business sale in the coming years.

Of course, there are requirements for who qualifies, and navigating the QSBS planning process can be complicated. But for many small businesses currently considering an exit strategy, it’s worth exploring. According to a recent report from the Exit Planning Institute, older business owners are the most likely to consider selling. 58% of baby boomers say they plan to sell their business in the next five years. That compares to 39% of Generation X and 48% of Millennials, 2023 data shows. But regardless of age, data shows that exit planning is a top priority for all generations of entrepreneurs.

First, the basics. The new law increases the cap on tax-free gains for qualified C-corp companies issuing stock after July 4 to $15 million from the previous threshold of $10 million. Additionally, the holding period for shares will be shortened from five years to three years, creating partial tax benefits for owners who sell after three or four years. This is important because it means that companies that are interested in selling before the five-year period but previously thought that QSBS was not an option could reconsider their strategy. Additionally, more small businesses are eligible as the asset cap has been increased from $50 million to $75 million – potentially making the option applicable to businesses that have not been eligible in the past. The law also provides for inflation adjustments.

Here are some more details on what small businesses need to know about how beneficial changes to the QSBS rules could make them more money if they decide to sell.

The tax calculation for S-Corporations and C-Corporations changes and can run into the millions

To qualify, companies must be incorporated as a C corporation. Many companies know very little about their corporate structure, but it can make a big difference for tax purposes. Therefore, understanding their structure is a crucial first step.

Before the Tax Cuts and Jobs Act and the One Big Beautiful Bill Act, it wasn’t attractive for small businesses to be C-corps, and many still aren’t organized that way, said Corey Pederson, wealth strategist at Crewe Advisors in Salt Lake City.

Rather, many opted for sole proprietorships or partnerships, which, with the exception of limited partners, are responsible for self-employment and personal taxes. According to the Small Business Administration, many companies also choose to be an S corporation, a special type of corporation designed to avoid the double tax penalty of a regular C corporation. S-corps allow profits and some losses to be passed through directly to the owners’ personal income without being subject to corporate tax rates. This type of incorporation became even more popular after tax law changes in 2017 allowed more companies to qualify for greater tax savings.

Now, however, more companies may have additional incentive to become a C corporation. “This widens the net for those who should be thinking about QSBS,” said Brian Gray, a partner at accounting firm Gursey Schneider in Los Angeles.

Owners can sell faster than the previous law allowed

U.S. taxpayers typically must pay federal capital gains taxes when they sell their company shares for a profit. But qualified small business stock offers significant federal tax benefits to entrepreneurs, startup founders, early employees and investors because they can exclude or defer capital gains taxes when selling qualified stock. With proper planning, the savings can be combined with other estate planning strategies for even greater tax savings, Gray said.

Many small businesses considering selling within a few years can receive millions in QSBS-related tax benefits by converting to a C corporation. These include domestic technology, manufacturing, wholesale and retail companies. In the past, owners had to hold the shares for five years to benefit from the tax benefits. However, the new law provides for a phased approach. After five years, shareholders receive 100% of the tax benefit. After four years they can get 75% of the benefit, after three years they can get 50%, which could make it more attractive to many owners, Gray said.

The disadvantage is double taxation

The main tax disadvantage of a C corporation is double taxation. This means that corporate profits are taxed at the company level and then taxed again when they are distributed as dividends to shareholders. However, there are ways to get around the problem of double taxation, so it makes sense to talk to a tax professional, Pederson said.

If you’ve been a small business owner for 10 to 20 years, chances are good that you have personal savings. Instead of taking profits out of the business, keep them in the business and use your personal savings for expenses, Pederson said. “If you don’t receive the distributions from the corporation, you don’t pay double tax,” he said, adding, “That doesn’t work if you don’t have enough savings to cover your expenses.”

According to the U.S. Census Bureau, as of 2023, there were two million small businesses—those with 500 employees or fewer—that were formally organized as corps. Many of these companies may benefit from additional savings as a result of the new tax law. According to the Exit Planning Institute, older business owners need to think carefully about the opportunity, especially given that 27% of boomer business owners say they are unprepared when it comes to formal valuation plans and 9% are unprepared when it comes to their estate plans.

And even if they’ve considered converting to a C corporation before and rejected the idea, it’s worth another look, said Natalie Whelton, senior wealth advisor and wealth strategist at HB Wealth in Atlanta, especially since the additional $25 million in headroom opens the door for more companies to convert to a C corporation, she added.

An necessary advance for Novo Nordisk’s GLP-1 capsule

Novo Nordisk flags fly in front of their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025.

Tom Little | Reuters

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health news straight to your inbox. Subscribe here to receive future editions.

A closely watched pill from Novo Nordisk has just received approval for another use: reducing cardiovascular risks.

The move also confirms that the highly popular GLP-1, in both oral and injectable forms, has additional health benefits beyond regulating blood sugar and promoting weight loss.

The Food and Drug Administration on Friday approved oral semaglutide to reduce the risk of serious cardiovascular complications such as heart attack, stroke or cardiovascular death in people with type 2 diabetes who are at high risk of these events. In the late-stage SOUL trial, a 14-milligram dose of the pill reduced the risk of these complications by 14% after four years compared to a placebo.

Oral semaglutide, sold under the name Rybelsus for diabetes, has been on the market since 2019 and remains the only approved GLP-1 pill. Semaglutide is also the active ingredient in Novo Nordisk’s blockbuster obesity injection Ozempic and obesity drug Wegovy, the latter of which is also approved for heart health in people with obesity and existing cardiovascular disease.

“Oral GLP-1 therapy to improve blood sugar control was an innovation in and of itself,” said Dr. John Buse, director of the Diabetes Care Center at the University of North Carolina School of Medicine and co-chair of the SOUL study steering committee, in a statement. “This new indication, based on the SOUL data, represents further progress and demonstrates the versatility of semaglutide while expanding options for millions of people.”

But all eyes are on another FDA decision due by year’s end: whether to approve oral semaglutide for obesity. Patients using blockbuster weight-loss drugs want a more convenient option that could ease the supply shortages and access barriers created by the expensive weekly injections currently prevalent.

Oral semaglutide is said to be the first-ever GLP-1 pill approved for the treatment of obesity, but a competitor to Eli Lilly called Orforglipron is not too far behind. In August, Eli Lilly CEO Dave Ricks said the company hoped to launch its pill globally “by this time next year.”

Wall Street is watching to see which pill could gain more market share as both have their own advantages. For example, in obesity studies, the effectiveness of Eli Lilly’s pill appeared to be slightly less than that of Novo Nordisk’s oral semaglutide.

But while Novo Nordisk’s pill is a peptide drug, Orforglipron is a small molecule drug.

This means that Eli Lilly’s pill is more easily absorbed by the body and does not require dietary restrictions like Novo Nordisk does. Some analysts have also said orforglipron will be easier to produce on a large scale, which is crucial as demand for obesity and diabetes injections outstrips supply.

Both Novo Nordisk and Eli Lilly are exploring their pills in other areas. Novo Nordisk is studying oral semaglutide in patients with Alzheimer’s disease. Meanwhile, Eli Lilly is studying orforglipron in separate trials in patients with obstructive sleep apnea and high blood pressure.

We’ll be watching both pills closely, so stay tuned for our coverage.

Feel free to send tips, suggestions, story ideas and data to Annika at a new email address: annika.constantino@versantmedia.com.

The latest in healthcare: Mark Cuban praises Trump for drug prices, blasts PBMs and gets taken to task by one

Mark Cuban speaks onstage during the 2025 SXSW Conference and Festival at the Hilton Austin on March 10, 2025 in Austin, Texas.

Julia Beverly | Wireimage | Getty Images

Mark Cuban says his startup Cost Plus Drugs will be one of the offerings on TrumpRx when the Trump administration’s new drug platform launches next year.

Although the billionaire entrepreneur said he is still not a fan of the president, he appreciates his attempts to lower drug prices and hopes the administration will go further. Cuban hopes that in addition to direct sales to consumers, the government will require insurers to count cash purchases of drugs toward patients’ deductibles.

I had the opportunity to sit down with Cuban on Sunday at the HLTH conference in Las Vegas for an in-depth conversation about drug pricing. He co-founded Cost Plus three years ago, as a shooter at Pharmacy Benefit Managers (PBMs), and he still rails against the middlemen. He claims they are “cheating” and driving up drug costs.

Well, on Monday one of the major PBMs criticized Cuban for his claims. CVS sent me a fact sheet comparing the TrueCost employer discount pass-through PBM model to Cost Plus pricing. Examples include the generic cholesterol drug atorvastatin, which costs about $6 on the CVS plan and $10 on the Cost Plus plan.

During an onstage session, Tilak Mandadi, CVS Health’s chief technology officer, told me that Cuban’s claims about PBMs were “bullshit,” citing savings on generic drugs the company offers employers through TrueCost.

He and Chief Medical Officer Dr. Amy Compton-Phillips argued that PBM rebates do not lead to higher drug costs, but rather that drug manufacturers are the ones setting high prices for specialty and brand-name drugs. Additionally, they told me, many of these pharmaceutical companies use CVS’s PBM discount services to contain costs for their own employees.

What were the chances of things getting hot in Vegas? You can bet the debate will continue beyond Sin City.

Here is an edited version of my conversation with Mark Cuban.

Speaking of drug pricing, could Novo Nordisk strike the next drug pricing deal?

Dave Moore, U.S. president of Novo Nordisk, confirmed that his company is “currently in active dialogue” with the Trump administration over so-called MFN pricing for its popular GLP-1 drugs Ozempic and Wegovy.

Last week, President Donald Trump said he would like to lower Ozempic’s cash price to $150, while Centers for Medicare & Medicaid Administrator Dr. Mehmet Oz, noted that nothing had been clarified yet.

During a meeting at HLTH, Moore would not provide details about pricing talks with the government over MFN pricing or the Medicare Inflation Reduction Act pricing negotiations that are just wrapping up this month. However, he said the company wants to work with the administration to provide better access for patients.

“I think there’s a shared sentiment among the president and the administration that we also want to make sure our medications are available,” Moore said, adding that he could envision the company’s Novocare direct-to-consumer side being part of TrumpRx.

“If we can work together on that … I think that’s a really positive step forward,” he said.

Novocare Pharmacy, the direct-to-consumer platform launched earlier this year, currently accounts for about 11% of the company’s Wegovy sales. Rival Eli Lilly’s direct-to-consumer website LillyDirect accounts for 35% of new sales of weight-loss drug Zepbound. Having both on TrumpRx could raise the profile of the companies’ cash sales programs even further.

These discussions are taking place as Novo Nordisk ramps up its manufacturing facilities in North Carolina in anticipation of FDA approval of its Wegovy pill. Moore said the company is ensuring it is able to meet demand when the time comes.

Watch my conversation with Moore here.

You can always send tips, suggestions, story ideas and data to Bertha at bertha.coombs@versantmedia.com.